AMCP provides feedback on CMS's proposal to redefine negotiated price as the lowest possible payment that a Part D plan will make to a pharmacy, inclusive of all price concessions.
On March 3, AMCP responded to a Request for Information from the Healthy Futures Subcommittee on Modernization, supporting legislative and regulatory solutions to remove barriers to coverage and payment for Digital Therapeutics in the Medicare program.
In this guest blog post, Tenicia Talley, PharmD, MSCR, discussespharmacoequity and how this applies to AMCP's efforts in addressing racial health disparities.
Mark McClellan, MD, PhD, was recently named 2022 Steven G. Avey Award recipient. The Avey award recognizes a managed care leader for sustained, exemplary, and distinguished service to the practice of pharmacy.
From thought-provoking keynote sessions to networking opportunities, AMCP CEO, Susan Cantrell, MHL, RPh, CAE, highlights what AMCP 2022 attendees can look forward to at the annual meeting.
On Feb. 14, AMCP joined a pharmacy stakeholder letter supporting Dr. Robert Califf's nomination for FDA Commissioner, a post he previously held in 2016.
On Feb. 9, AMCP submitted comments to CMS supporting the agency's proposal to cover anti-amyloid monoclonal antibodies through the Coverage with Evidence Development pathway.